Sobi acquires Dova in $915M hematology franchise play by Kyle Blankenship Monday, September 30, 2019 Swedish pharma Sobi is looking for a leg up in hemotology. Can a $915 million buyout of Dova—and its so-far-underperforming drug Doptelet—do the trick?
Sobi rolls more data backing new rare disease drug Gamifant by Carly Helfand Monday, December 3, 2018 Last month, Sobi snagged an FDA approval for rare disease drug Gamifant. And Monday, it unveiled more of the data that secured the agency’s favor.
